RGTA® (ReGeneraTing Agent), are intelligent engineered biopolymers that optimize the natural potential of mammals to regenerate tissues by replacing destroyed natural sugars and protecting the natural signals needed for tissue regeneration. RGTA is a new therapeutic class of products based on preservation of the cellular environment or extra-cellular matrix. RGTA belongs to matrix therapy technology a new field in regenerative medicine.

RGTA technology was invented by Professors Denis Barritault and Jean Pierre Caruelle, both professors at the university of Paris XII and directors of the CRRET, a CNRS associated laboratory.

RGTA technology is the fruit of 150 man-years of work involving an international network of 12 academic laboratories which has already published 60 scientific articles (see publications).